Early stage IT and Healthcare Investing

Labrys Biologics

portfoliocompanies

company snapshot

Labrys

Labrys Biologics is a private, venture-financed development stage biotechnology company focused on treatments for chronic migraine. Labrys' lead candidate, LBR-101 (formerly known as RN-307), is an anti-CGRP monoclonal antibody which has completed Phase 1.

Facebook Google+ Twitter Email LinkedIn Share